- Seizures excluding absence seizures
- Tablet:
- Adult: 60-180mg nocte
- Children: 5-8mg/kg
- IV/IM:
- 300-800 mg OR 15-20 mg/kg/dose
- Tablet:
- Status epilepticus (after benzodiazepines and phenytoin fail):
- IV: 10-20 mg/kg every 20 min PRN. Max per dose: 1 g. Dose to be administered at a rate not more than 100 mg/minute. Injection to be diluted 1 in 10 with water for injection.
- Sedation:
- 30-120 mg/day PO BD/TDS. Max 400 mg/day
- Insomnia:
- 100-200 mg PO nocte. Max 400 mg/day
Injection: 200mg/ml
Tablet: 30mg
To be taken at night.
CAUTION:
Women of child-bearing potential.
Barbiturate anticonvulsant.
It may have the ability to enhance the inhibitory synaptic action of GABA.
- Respiratory depression with IV
- Drowsiness
- Lethargy
- Hyperactivity with pediatric patients.
- Fatigue
- Ataxia
- Erythema multiforme
- Stevens-Johnson syndrome
- Withdrawal symptoms with abrupt discontinuation
- Dependence
- Excitement, confusion and depression in geriatric patients
- Hypersensitivity to excipients
- Porphyria
- Severe hepatic impairment
- Respiratory depression
- Intra-arterial depression
- History of addiction on sedative-hypnotics
- Large doses in nephritic patients
- Artemether/lumefantrine
- Atazanavir
- Praziquantel
- Voriconazole
- Mexiletine
- Phenylbutazone
- Metronidazole
- Ritonavir
- Tenofovir
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D; Contraindicated |
| Breastfeeding | Do not nurse |
| Schedule | Controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Barbit | 200mg/mL | Injection | 5’s | Incepta Pharma | Radiance Pharma |
| Phenbital | 30mg | Tablet | 100’s, 1000’s | Dawa Ltd | Dawa Ltd |
| Phenobarb | 30mg | Tablet | 1000’s | Universal Corporation | Universal Corporation |
| Phenobarbital | 30mg | Tablet | 100’s | Cosmos Ltd | Cosmos Ltd |
| Phenobarbitone | 30mg | Tablet | 100’s, 1000’s | Biodeal Labs | Biodeal Labs |
| Phenobarbitone | 30mg | Tablet | 100’s | Laboratory & Allied | Laboratory & Allied |